At the beginning of 1994, the Massachusetts General Hospital (MGH) of the Harvard Medical School in Boston (MA, USA) a pioneer in proton therapy since 1959, selected a team led by Ion Beam Applications SA (IBA) to supply the proton therapy equipment of its new Northeast Proton Therapy Centre (NPTC). The IBA integrated system includes a compact 235 MeV isochronous cyclotron, a short energy selection system transforming the fixed energy beam extracted from the cyclotron into a variable energy beam, one or more isocentric gantries fitted with a nozzle, a system consisting of one or more horizontal beam lines, a global control system including an accelerator control unit and several independent but networked therapy control stations, a global safety management system, and a robotic patient positioning system. The present paper presents the equipment being built for the NPTC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0924-4212(96)84917-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Gastroesophageal Reflux in Infants and Children: Diagnosis and Treatment.
Am Fam Physician
January 2025
Duke University School of Medicine, Durham, N.C.
Gastroesophageal reflux is a common physiologic event in infants in which gastric contents pass from the stomach into the esophagus. Gastroesophageal reflux may be asymptomatic or cause regurgitation or "spit up." This occurs daily in approximately 40% of infants.
View Article and Find Full Text PDFPhysiopathological effects of entrance versus distal spread-out Bragg peak on mouse spinal cord neurons.
Sci Rep
January 2025
Department of Biomedical and Biotechnological Sciences, University of Catania, 95123, Catania, Italy.
Recent investigations into radiation-induced side effects have focused on understanding the physiopathological consequences of irradiation on late-responding tissues like the spinal cord, which can lead to chronic progressive myelopathy. Proton therapy, an advanced radiation treatment, aims to minimize damage to healthy tissues through precise dose deposition. However, challenges remain, particularly regarding the variation in dose distribution, characterized by maximum deposition at the end of the proton range, known as the distal fall-off of a spread-out Bragg peak.
View Article and Find Full Text PDFLong-term survival and risk factors of synchronous bone metastasis in oral tongue squamous cell carcinoma patients.
Eur J Cancer Prev
January 2025
Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital.
The objective of this study was to analyze the risk factors for synchronous bone metastases in patients with oral tongue squamous cell carcinomas (OTSCC). OTSCC patients were extracted from the Surveillance, Epidemiology and End Results database between 2014 and 2017. We examined the association between risk factors and synchronous bone metastases using Chi-squared tests.
View Article and Find Full Text PDFEnhancing precision in lacrimal sac tumor management through integration of multimodal imaging and intensity modulated proton therapy.
Med Dosim
January 2025
Department of Radiation Oncology, Peking University First Hospital, Beijing, China. Electronic address:
This study presents a patient with a PET-CT detected residual lacrimal sac tumor who was treated with intensity modulated proton therapy (IMPT) and concurrent chemotherapy. The patient a 49-year-old male diagnosed with squamous cell carcinoma of the left lacrimal sac had under-went endoscopic surgery. Postoperative PET-CT implied tumor residual in the left lacrimal sac.
View Article and Find Full Text PDFDelineating CYP2C19-Mediated Interactions: Network Pharmacology Investigation of Ilaprazole and Clopidogrel versus Conventional Proton Pump Inhibitors.
Curr Drug Discov Technol
December 2024
Department of Pharmacy Practice, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur, Chengalpattu District, Tamilnadu, 603203, India.
Background: Clopidogrel, an antiplatelet drug commonly used in cardiovascular disease, is metabolized by the liver mainly through CYP2C19. Concomitant use of Proton pump inhibitors along with clopidogrel may affect the potency of clopidogrel by CYP2C19 inhibition. However, a novel PPI, ilaprazole is known to differ in its pharmacokinetic features, given the potential differences between ilaprazole's interactions and their metabolism with clopidogrel.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!